Orally active inhibitors of human leukocyte elastase. III. Identification and characterization of metabolites of L-694,458 by liquid chromatography-tandem mass spectrometry

Drug Metabolism and Disposition

Volumn 25, Issue 8, 1997, Pages 940-952

  Luffer Atlas, Debra ^a   Vincent, Styliani H ^b   Painter, Susan K ^b   Arison, Byron H ^b   Stearns, Ralph A ^b   Chiu, Shuet Hing Lee ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ENZYME INHIBITOR; LEUKOCYTE ELASTASE; N [(1,3 BENZODIOXOL 5 YL)BUTYL] 3,3 DIETHYL[4 [(4 METHYL 1 PIPERAZINYL)CARBONYL]PHENOXY] 4 OXO 1 AZETIDINECARBOXAMIDE; N [1 (1,3 BENZODIOXOL 5 YL)BUTYL] 3,3 DIETHYL 2 [4 [(4 METHYL 1 PIPERAZINYL)CARBONYL]PHENOXY] 4 OXO 1 AZETIDINECARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEALKYLATION; DRUG BILE LEVEL; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER MICROSOME; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RHESUS MONKEY; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ANIMALS; AZETIDINES; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; HUMANS; LEUKOCYTE ELASTASE; LIVER; MACACA MULATTA; MALE; MASS SPECTROMETRY; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; MACACA MULATTA;

EID: 0030745408     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. G. L. Snider: Protease-antiprotease imbalance in the pathogenesis of emphysema and chronic bronchial injury: a potential target for drug development. Drug Dev. Res. 10, 235-253 (1987).
2. A. H. Jackson, S. L. Hill, S. C. Afford, and R. A. Stockley: Sputum soluble phase proteins and elastase activity in patients with cystic fibrosis. J. Respir. Dis. 65, 114-124 (1984).
3. D. A. Trainor: Synthetic inhibitors of human neutrophil elastase. Trends Pharmacol. Sci. 8, 303-307 (1987).
4. W. K. Hagmann, L. A. O'Grady, B. M. Ashe, M. E. Dahlgren, H. Weston, A. L. Maycock, W. B. Knight, and J. B. Doherty: Inhibition of human leukocyte elastase by C-2 substituted cephalosporin sulfones. Eur. J. Med. Chem. 24, 599-604 (1989).
5. R. A. Firestone, P. L. Barker, J. M. Pisano, B. M. Ashe, and M. E. Dahlgren: Monocyclic β-lactam inhibitors of human leukocyte elastase. Tetrahedron 7, 2255-2262 (1990).
6. P. Davies, B. M. Ashe, R. J. Bonney, C. Dorn, P. Finke, D. Fletcher, W. A. Hanlon, J. L. Humes, A. Maycock, R. A. Mumford, M. A. Navia, E. E. Opas, S. Pacholok, S. Shah, M. Zimmerman, and J. B. Doherty: The discovery and biologic properties of cephalosporin-based inhibitors of PMN elastase. Ann. N.Y. Acad. Sci. 625, 219-229 (1991).
7. W. B. Knight, R. Chabin, and B. Green: Inhibition of human serine proteases by substituted 2-azetidinones. Arch. Biochem. Biophys. 296, 704-708 (1992).
8. J. B. Doherty, S. K. Shah, P. E. Finke, C. P. Dorn, W. K. Hagmann, J. J. Hale, A. L. Kissinger, K. R. Thompson, K. Brause, G. O. Chandler, W. B. Knight, A. L. Maycock, B. M. Ashe, H. Weston, P. Gale, R. A. Mumford, O. F. Andersen, H. R. Williams, T. E. Nolan, D. L. Frankenfield, D. Underwood, K. P. Vyas, P. H. Kari, M. E. Dahlgren, J. Mao, D. S. Fletcher, P. S. Dellea, K. M. Hand, D. G. Osinga, L. B. Peterson, D. T. Williams, J. M. Metzger, R. J. Bonney, J. L. Humes, S. P. Pacholok, W. A. Hanlon, E. Opas, J. Stolk, and P. Davies: Chemical, biochemical, pharmacokinetic, and biological properties of L-680,833: a potent, orally active monocyclic β-lactam inhibitor of human polymorphonuclear leukocyte elastase. Proc. Natl. Acad. Sci. USA 90, 8727-8731 (1993).
9. S. K. Shah, C. P. Dorn, P. E. Finke, J. J. Hale, W. K. Hagmann, K. A. Brause, G. O. Chandler, A. L. Kissinger, B. M. Ashe, H. Weston, W. B. Knight, A. L. Maycock, P. S. Dellea, D. S. Fletcher, K. M. Hand, R. A. Mumford, D. J. Underwood, and J. B. Doherty: Orally active β-lactam inhibitors of human leukocyte elastase. 1. Activity of 3,3-diethyl-2-azetidinones. J. Med. Chem. 35, 3745-3754 (1992).
10. W. K. Hagmann, A. L. Kissinger, S. K. Shah, P. E. Finke, C. P. Dorn, K. A. Brause, B. M. Ashe, H. Weston, A. L. Maycock, W. B. Knight, P. S. Dellea, D. S. Fletcher, K. M. Hand, D. Osinga, P. Davies, and J. B. Doherty: Orally active β-lactam inhibitors of human leukocyte elastase. 2. Effect of C-4 substitution. J. Med. Chem. 36, 771-777 (1993).
11. P. E. Finke, S. K. Shah, D. S. Fletcher, B. M. Ashe, K. A. Brause, G. O. Chandler, P. S. Dellea, K. H. Hand, A. L. Maycock, D. G. Osinga, D. J. Underwood, H. Weston, P. Davies, and J. B. Doherty: Orally active β-lactam inhibitors of human leukocyte elastase. 3. Stereospecific synthesis and structure-activity relationships for 3,3-dialkylazetidin-2-ones. J. Med. Chem. 38, 2449-2462 (1995).
12. B. G. Breen, H. Weston, B. M. Ashe, J. Doherty, P. Finke, W. Hagmann, M. Lark, J. Mao, A. Maycock, V. Moore, R. Mumford, S. Shah, L. Walakovits, and W. B. Knight: PMN Elastases: A comparison of the specificity of human isozymes and the enzyme from other species toward substrates and inhibitors. Arch. Biochem. Biophys. 286, 284-292 (1991).
13. S. H. Vincent, S. K. Painter, D. Luffer-Atlas, B. V. Karanam, G. A. Doss, E. McGowan, C. Cioffe, and S. H. L. Chiu: Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys. Drug Metab. Dispos., 25, 932-939 (1997).
14. R. J. Cvetovich, M. Chartrain, F. W. Hartner, Jr., C. Roberge, J. S. Amato, and E. J. J. Grabowski: An asymmetric synthesis of L-694,458, a human leukocyte elastase inhibitor, via novel enzyme resolution of β-lactam esters. J. Org. Chem. 61, 6575-6580 (1996).
15. R. W. Wang, P. H. Kari, A. Y. H. Lu, P. E. Thomas, F. P. Guengerich, and K. P. Vyas: Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A as the major enzyme responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. 290, 355-361 (1991).
16. P. O. Seglen: Preparation of isolated rat liver cells. In "Methods in Cell Biology," vol. 19 (D.M. Prescot, ed.), pp. 29-83. Academic Press, New York, 1976.
17. R. Weinshilboum: Methyltransferase pharmacogenetics. Pharmacol. Ther. 43, 77-90 (1989).
18. U. Breyer: Accumulation and elimination of a novel metabolite during chronic administration of the phenothiazine drug perazine to rats. Biochem. Pharmacol. 21, 1419-1429 (1972).
19. U. Breyer, A. Prox, R. Bertele, and H. J. Gaertner: Tissue metabolites of trifluoperazine, fluphenazine, prochlorperazine and perphenazine in the rat: identification and synthesis. J. Pharm. Sci. 63, 1842-1848 (1974).
20. H. J. Gaertner and U. Breyer: In vivo piperazine ring degradation in neuroleptic and antihistaminic drugs. Arzneim.-Forsch. (Drug Res.) 22, 1084-1085 (1972).
21. H. J. Gaertner, U. Breyer, and G. Liomin: Chronic administration of chlorcyclizine and meclizine to rats: Accumulation of a metabolite formed by piperazine ring cleavage. J. Pharmacol. Exp. Ther. 185, 195-201 (1973).
22. G. Miyamoto, H. Sasabe, N. Tominaga, N. Uegaki, M. Tominaga, and T. Shimizu: Metabolism of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212) in the rat, mouse, dog, monkey and human. Xenobiotica 18, 1143-1155 (1988).
23. E. W. Gascoigne, G. J. Barton, M. Michaels, W. Meuldermans, and J. Heykants: The kinetics of ketoconozole in animals and man. Clin. Res. Rev. 1, 177-187 (1981).
24. A. L. Hume and T. M. Kerkering: New drug evaluations: Ketoconozole. Drug Intell. Clin. Pharm. 17, 169-174 (1983).
25. L. W. Whitehouse, A. Menzies, B. Dawson, T. D. Cyr, A. W. By, D. B. Black, and J. Zamecnik: Mouse hepatic metabolites of ketoconozole: isolation and structure elucidation. J. Pharm. Biomed. Anal. 12, 1425-1441 (1994).
26. T. A. Baillie, E. Neill, H. Hughes, D. L. Davies, and D. S. Davies: Application of stable isotope labeling in studies of the metabolism of clonidine in rat liver. In "Stable Isotopes: Proceedings of the Third International Conference." pp. 415-425. Academic Press, New York, 1979.
27. W. B. Knight, B. G. Green, R. M. Chabin, P. Gale, A. L. Maycock, H. Weston, D. W. Kuo, W. M. Westler, C. P. Dorn, P. E. Finke, W. K. Hagmann, J. J. Hale, J. Liesch, M. MacCoss, M. A. Navia, S. K. Shah, D. Underwood, and J. B. Doherty: Specificity, stability, and potency of monocyclic β-lactam inhibitors of human leucocyte elastase. Biochem. 31, 8160-8170 (1992).
28. R. Chabin, B. G. Green, P. Gale, A. L. Maycock, H. Weston, C. P. Dorn, P. E. Finke, W. K. Hagmann, J. J. Hale, M. MacCoss, S. K. Shah, D. Underwood, J. B. Doherty, and W. B. Knight: Mechanism of inhibition of human leucocyte elastase by monocyclic β-lactams. Biochemistry 32, 8970-8980 (1993).
29. B. G. Green, R. Chabin, S. Mills, D. J. Underwood, S. K. Shah, D. Kuo, P. Gale, A. L. Maycock, J. Liesch, C. S. Burgey, J. B. Doherty, C. P. Dorn, P. E. Finke, W. K. Hagmann, J. J. Hale, M. MacCoss, W. M. Westler, and W. B. Knight: Mechanism of inhibition of human leucocyte elastase by β-lactams. 2. Stability, reaction kinetics, and products of β-lactam-derived E-I complexes. Biochemistry 34, 14331-14343 (1995).
30. D. J. Underwood, B. G. Green, R. Chabin, S. Mills, J. B. Doherty, P. E. Finke, M. MacCoss, S. K. Shah, C. S. Burgey, T. A. Dickinson, P. R. Griffin, T. E. Lee, K. M. Swiderek, T. Covey, W. M. Westler, and W. B. Knight: Mechanism of inhibition of human leucocyte elastase by β-lactams. 3. Use of electrospray ionization mass spectrometry and two-dimensional NMR techniques to identify β-lactam-derived E-I complexes. Biochemistry 34, 14344-14355 (1995).